Arbutus Reports Q3 2026 Results and Lifts FDA Hold on AB-101
Arbutus reported an updated cash position of $337.5M and achieved a significant milestone with FDA approval to resume work on oral candidate AB-101.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed